STERIS Plans Restructuring Of Healthcare Surgical Business In Europe, Other Actions
STERIS Plans Restructuring Of Healthcare Surgical Business In Europe, Other Actions
STERIS today is also announcing a targeted restructuring plan, which includes restructuring of the Healthcare surgical business in Europe, as well as other actions including impairment of an internally developed X-ray accelerator, product rationalizations and facility consolidations.
STERIS今天还宣布了一项有针对性的重组计划，其中包括重组欧洲医疗外科业务，以及其他行动，包括对内部开发的X射线加速器进行减值、产品合理化和设施整合。
The Company anticipates total pre-tax restructuring charges of approximately $100 million with $44.4 million recorded in the fiscal 2024 fourth quarter and the balance expected to be recorded in fiscal 2025. The restructuring plan will be excluded from adjusted earnings per diluted share. Of the $100 million charge, approximately $50 million is non-cash. EBIT improvement resulting from these actions is anticipated to be approximately $25 million per year, with the majority of the benefit being in fiscal 2026 and beyond due to the timing of actions.
该公司预计，税前重组费用总额约为1亿美元，其中4440万美元将在2024财年第四季度入账，余额预计将在2025财年入账。重组计划将不包括在调整后的摊薄后每股收益中。在1亿美元的费用中，约有5000万美元是非现金。这些行动带来的息税前利润预计每年将增加约2500万美元，其中大部分收益将出现在2026财年及以后，这是由于行动时机所致。